Advertisement

Pentoxifyllin

  • C. Hock
  • F. Müller-Spahn

Zusammenfassung

Pentoxifyllin (1-(5-oxyohexyl)-3,7dimethylxanthine, 1-(5-oxyohexyl)theobromine), ein Methylxanthin-Derivat, ist ein in der Mikrozirkulation wirksames Hämorheologicum, das zu einer Senkung der Blutviskosität, Normalisierung der verminderten Erythrozytenverformbarkeit sowie Hemmung der Erythrozytenund Thrombozytenaggregation führt. Zu den Wirkungen gehören ferner die Stimulierung der Freisetzung von Prostazyklin in vitro, die Hemmung der Freisetzung plättcheneigener Mediatoren, die Senkung erhöhter Fibrinogenspiegel, die Verminderung der Adhäsivität der Leukozyten am Endothel sowie die Verminderung der Leukozytenaktivierung und dadurch bedingte Endothelschäden. In der derzeitigen Therapieforschung steht die Untersuchung des therapeutischen Potentials von der durch Pentoxifyllin bedingten Hemmung des Tumor-Nekrosefaktors (TNF)-α und Effekte auf Immunmodulatoren im Vordergrund.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aviado DM, Porter JM (1984) Pentoxifylline: a new drug for the treatment of intermittent claudication — mechanisms of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297–307PubMedGoogle Scholar
  2. Andreeva NJ, Gegutschadze MD, Gelashwili AP, Yipiani VA, Natadze TG et al. (1979) The effect of pentoxifylline on regional vascular systems. Curr Med Res Opin 6 [Suppl 4]: 57–59CrossRefGoogle Scholar
  3. Angelides NS (1986) Continuous infusion treatment with pentoxifylline in patients with severe peripheral vascular occlusive disease. Angiology 37: 555–564PubMedCrossRefGoogle Scholar
  4. Angelkort B (1977) Influence of pentoxifylline (Trental 400) on microcirculation, post-stenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease. IRCS Med Sci 5: 370Google Scholar
  5. Angelkort B (1979) Thrombozytenfunktion, plasmatische Blutgerinnung und Fibrinolyse bei chronisch arterieller Verschlußkrankheit. Med Welt 30: 1239–1248PubMedGoogle Scholar
  6. Angelkort B (1981) Coagulation phenomena and blood fluidity in peripheral occlusive arterial disease. Study with pentoxifylline. In: Manrique U, Müller WE (eds) Disorders of blood flow; new therapeutic aspects. Excerpta Medica, Amsterdam, pp 68–79Google Scholar
  7. Angelkort B, Doppelfeld E (1983) The treatment of chronic arterial occlusion: a clinical study with a new formulation of pentoxifylline (Trental 400). Pharmatherapeutica 3 [Suppl I]: 18–29Google Scholar
  8. Arzneimittelkompendium der Schweiz (1996) Black RS, Barclay LL, Nolan KA, Thaler HW, Hardiman ST, Blass JP (1992) Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 40:237–244Google Scholar
  9. Bluhm RE, Molnar J, Cohen MM (1985) The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain. Clin Neuropharmacol 8: 280–285PubMedCrossRefGoogle Scholar
  10. Bluhm RE, Cohen MM (1978) Protection by pentoxifylline against ischemic deterioration of cerebral metabolism. Neurology 28: 378Google Scholar
  11. Flamm P, Lehrach F, Weiser HG (1978) Durchblutungsstörungen des Netzhaut-Aderhaut-Bereichs und ihre Behandlungsmöglichkeiten mit Pentoxifylline. Therapiewoche 28: 9911–9918Google Scholar
  12. Gabaschwili VM, Kobaladze SG, Schakaraschwili RR, Virsaladze MD, Petriaschwili SP et al. (1979) The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. Curr Med Res Opin 6 [Suppl 4]: 25–29CrossRefGoogle Scholar
  13. Hartmann A (1985) Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and codergocrine mesylate in patients with chronic cerebrovascular disease. Curr Med Res Opin 9: 475–479PubMedCrossRefGoogle Scholar
  14. Hartmann A (1986) Haemorheoiogical treatment of acute cerebral ischaemia. In: Gotoh Y, Lechner H (eds) Clinical haemorheology — a new approach to cerebrovascular disease. Royal Society of Medicine Services, London, pp 65–73Google Scholar
  15. Hartmann A, Alberti E, Lange D (1979) Effect of pentoxifylline on regional CBF and CBV in dementia. Acta Neurol Scand 60 [Suppl 72]: 624–625Google Scholar
  16. Herskovits E, Vazquez A, Famulari A, Tamaroff L, Fraiman H, Gonzales AM et al. (1980) A randomised clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks. A one-year follow-up. Proceedings of Conference on Blood Rheology and Microcirculation, Capri, ItalyGoogle Scholar
  17. Hinze HJ (1971a) Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine, part 1. The spectroscopy of 3,7-dimethyl-1-(oxo-hexyl)-xanthine. Arzneimittelforschung/Drug Res 21: 1456–1459Google Scholar
  18. Hinze HJ (1971b) Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine, part 2. Chromatography and quantitative estimation of BL 191. Arzneimittelforschung/Drug Res 21: 2045Google Scholar
  19. Hinze HJ (1972) The pharmacokinetics of 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (BL 191) in man. Arzneimittelforschung/Drug Res 22: 1492–1495Google Scholar
  20. Hinze HJ, Bedessem G, Sdder A (1972) Structure of the excretion products of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191) in man. Arzneimittelforschung/Drug Res 22: 1144–1151Google Scholar
  21. Hinze HJ, Grigoleit HG, Rethy B (1976) Bioavailability and pharmaeokinetics of pentoxifylline from Trental 400 in man. Pharmatherapeutica 1: 160–171Google Scholar
  22. Huppertz M (1976) Klinische Erfahrungen mit einem neuen Xanthinderivat (BL 191) bei der Behandlung akuter Hörminderungen oder Ertaubungen. Therapiewoche 23: 5008–5017Google Scholar
  23. Janaki S (1980) Pentoxifylline in strokes: a clinical study. J lnt Med Res 8: 56–62Google Scholar
  24. Keller H (1983) Treatment of chronic arterial circulatory disorders: double-blind trial with pentoxifylline (Trental 400). Pharmatherapeutica 3 [Suppl I]: 67–73Google Scholar
  25. Koppenhagen K, Wenig HG, Müller K (1977a) Measurement of cerebral blood flow following intravenous administration of pentoxifylline (Trental). Curr Med Res Opin 4: 521–528PubMedCrossRefGoogle Scholar
  26. Koppenhagen K, Wenig HG, Müller K (1977b) The effects of pentoxifylline (Trental) on cerebral blood flow: a double-blind study. Curr Med Res Opin 4: 681–687CrossRefGoogle Scholar
  27. Lehrach F, Miller R (1981) Ergebnisse der klinischen Prüfung des Vasotherapeutikums 3,7-Dimethyl-1-(S-Oxohexyl)-xanthin. Arzneimittelforschung/Drug Res 21: 1171–1173Google Scholar
  28. Maak G (1986) Ambulante Hörsturztherapie mit Dextran und Pentoxifylline. Therapiewoche 36: 3347–3351Google Scholar
  29. Pettegrew J, Kopp S, Glonek T (1983) P-31 nuclear magnetic resonance study of pentoxifylline effect on experimental cerebral ischemia. Neurology 33 [Suppl 2]: 152Google Scholar
  30. Samlaska CP, Winfield EA (1994) Pentoxifylline. J Am Acad Dermatol 30:603–621PubMedCrossRefGoogle Scholar
  31. Ward A, Clissold SP (1987) Pentoxifylline — a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50–97PubMedCrossRefGoogle Scholar
  32. Wenig HG, Koppenhagen K (1981) Effects of pentoxifylline on cerebral and hepatic blood flow: scintigraphic measurements in patients with cerebrovascular insufficiency and liver diseases. In: Manrique U, Müller WE (eds) Disorders of blood flow: new therapeutic aspects. Excerpta Medica, Amsterdam, pp 95–106Google Scholar
  33. Wilt SG, Milward E, Zhou JM, Nagasato K, Patton H, Rüsten R, Griffin DE, O’Connor M, Dubois-Dalcq M (1995) In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 37: 381–394PubMedCrossRefGoogle Scholar
  34. Yaya R, Aznar J, Vaya A, Villa P, Santos T et al. (1985) Effect of di-pyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency. Thromb Haemost 54: 896PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • C. Hock
  • F. Müller-Spahn

There are no affiliations available

Personalised recommendations